Noteworthy - Pharmaceutical Executive



Surviving the Emerging Market Price Wars: Three Myths & Three Lessons

June 29, 2014

How big Pharma stalwarts can avoid a corrosive battle of attrition with local competitors and instead obtain the long-term goal of a stable pricing environment.

Adaptive Trial Design: Prepping for Adoption

June 19, 2014

As interest grows in this productivity-enhancing tool for seamless drug development, there is a need for a better working consensus on standardized metrics that monitor progress and certify success.

Promoting Adherence: From Force to Finesse

June 16, 2014

Non-adherence, in the US alone, is a $100-billion-a-year problem. Healthcare players are touting patient education and engagement as the keys to better adherence rates. Ben Comer reports.

What Price Innovation?

June 16, 2014

Payers are seeking clear assessment of drug value to rationalize high drug prices. This issue has moved to center stage due to mounting concern over the high price for Gilead's Sovaldi, writes Jill Wechsler.

Pharma 50 Trends: Past, Present, and Future

June 9, 2014

Finding the correct coordinates for big Pharma's endless cycle of re-positioning is just as important as a winning scientific hand, writes William Looney.

Pharm Exec's Pharma 50 2014

June 9, 2014

For those companies in this year's Pharm Exec Top 50, meeting the accelerating market demand for specialty products has become an acute strategic imperative.

Immunotherapies: The New Hope for Cancer Treatment

June 9, 2014

The Cancer Research Institute is clearing a path to the future of immunotherapeutics. Ben Comer speaks to its CEO and director of scientific affairs, Jill O'Donnell-Tormey

India: Too Big to Overlook

June 2, 2014

India must still be included in the list of promising potential markets for global pharma manufacturers, writes Jill E. Sackman and Michael Kuchenreuther.

Oncology Biomarker Testing: Why the UK Delay?

May 29, 2014

Amy Butcher investigates why the UK is lagging significantly behind Europe in the uptake of oncology biomarker testing — and looks at what the delays mean for pharma.


Click here